Google_______________

Predictors of Sexual Transmission of HCV in Gay Men

Sexual transmission of hepatitis C virus (HCV) is rare between monogamous heterosexual couples, but recent reports from the United Kingdom and Europe suggest that it is more common among men who have sex with men, especially those coinfected with HIV.

Previous studies have shown that sexual transmission is associated with various sexual practices, a higher number of sexual partners, recreational drug use, and concurrent sexually transmitted infections.

In the August 2006 issue of Sexually Transmitted Infections, researchers with the Centre for Sexual Health and HIV Research in London shed further light on risk factors that predict HCV transmission among gay and bisexual men.

The Sex, Health and Antiretrovirals Project (SHARP) was a cross-sectional study of sexual behavior in HIV positive men who have sex with men attending a London outpatient clinic. Between July 1999 and August 2000, participants completed a self-administered computer-assisted questionnaire about recent sexual behavior, recreational drug use, and their last two sexual episodes involving different partners. Results were combined with routine clinical data and testing for HCV through April 2005. Among the 422 men who completed the questionnaire, 308 had sufficient clinical and HCV testing data available for analysis.

Results

Of the 308 men with adequate data, incident HCV infection -- defined as HCV antibody seroconversion or detectable HCV RNA following a previous negative test -- was identified in 11 men.

Factors associated with recent HCV infection were:

- unprotected anal intercourse;
- more than 30 sexual partners in the past year (P = 0.023);
- higher number of new anal sex partners in the past month;
- fisting (P < 0.001; adjusted relative risk 9.39);
- use of sex toys (P = 0.016);
- rimming (oral-anal sex) (P = 0.047);
- intranasal recreational drug use (P = 0.042).

In a multivariate analysis controlling for other factors, only fisting remained significantly associated with HCV (adjusted relative risk 6.27; P = 0.005).

In contrast with some previous studies, there was no observed association between HCV diagnosis and frequenting public sex venues such as saunas, sex clubs, or cruising grounds. There was also no apparent association with injection drug use during the past five years.

Conclusion

In conclusion, the authors wrote, "In this study of HIV positive [men who have sex with men], fisting is strongly associated with HCV infection. Where individuals report high-risk sexual behaviors, clinicians should offer appropriate testing for HCV infection."

HIV positive men who practiced anal fisting were about six times more likely to be infected with HCV. Fisting may promote infection by damaging the rectal lining, facilitating entry of the virus. However, most men who practiced fisting also engaged in other potentially high-risk sexual practices (making it difficult to determine which activities were responsible for transmission), and five of the men who contracted HCV did not report fisting.

"Fisting is not an isolated sexual practice, but one component of a larger sexual episode that probably includes several different sexual practices," the researchers wrote. "HCV infection may occur when mucosal disruption as a consequence of receptive fisting occurs and is followed by receptive unprotected anal intercourse either within the same sexual episode or another one."

Since interferon-based hepatitis C therapy is highly effective when starting during acute infection, they recommended that, "consideration should be given to HCV RNA screening in individuals identified as being at high sexual risk, detecting acute infection before anti-HCV antibody seroconversion."

8/18/06

Reference
J M Turner, A T Rider, J Imrie, and others. Behavioral predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV-positive men who have sex with men. Sexually Transmitted Infections 82(4): 298-300. August 2006.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin